touchCARDIO coverage of ESC Congress 2026
This content has been developed independently by Touch Medical Media for touchCARDIO. It is not affiliated with the ESC. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Latest Sections
We report on the latest data presented at the congress, and what it could mean for clinical practice.
Immediate 14-day ambulatory ECG monitoring did not significantly reduce recurrent syncope at 1 year in the ASPIRED trial, but it more than doubled the detection of clinically significant arrhythmias and enabled earlier diagnosis and treatment. Prof. Matthew Reed shares insights into the origins of ASPIRED, the importance of earlier investigation for patients with syncope, and how this approach might be incorporated into routine care.
Part 2
The PRESC1SE-MI trial found that a 0/1-hour pathway for assessing patients with suspected myocardial infarction was non-inferior to a more conservative 0/3-hour pathway for safety, but did not reduce the time patients spent in the emergency department.
The European Society of Cardiology (ESC) has published its first dedicated clinical practice guidelines on cardiac rehabilitation, calling for rehabilitation to be considered a core component of care across a broader range of cardiovascular conditions.
Phase IIb LUMINARA data presented at ESC Congress 2026 suggest that AZD5462 may improve cardiac remodeling and hemodynamics across different heart failure phenotypes, with the lowest dose producing the strongest remodeling signal in HFrEF. Prof. James Januzzi shares his expert insights.
Part 7
The European Society of Cardiology (ESC) has published new guidelines for the management of heart failure (HF), presented today at ESC Congress 2026 in Munich. The guidelines replace the 2021 recommendations and introduce new classifications for HF stages, phenotypes and therapies.
Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events compared with placebo in the overall CARDIO-TTRansform population, according to late-breaking results presented at ESC Congress 2026 in Munich, Germany.
Part 9
Direct oral anticoagulant (DOAC) therapy reduced adverse clinical events compared with no anticoagulation in patients with atrial fibrillation (AF) at intermediate risk of stroke, according to results from the SINGLE-AF trial presented during a Hot Line session at ESC Congress 2026.
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
We’re onsite at ESC Congress 2026 to speak with leading experts about the latest data, emerging insights and what they could mean for clinical practice.
Dr Jonathan Piccini discusses rhythm control in patients with atrial fibrillation and heart failure with preserved ejection fraction, the growing role of catheter ablation, and the evidence still needed to define its impact on cardiovascular outcomes.
At ESC Congress 2026, Prof. Rami Abu Fanne (Hillel Yaffe Medical Center and Hadassah Medical Center, The Hebrew University of Jerusalem) presented an analysis exploring whether baseline vitamin D levels were associated with metabolic response to semaglutide in people with type 2 diabetes.
Prof. Arnoud van ’t Hof discusses the CELEBRATE trial, the potential benefits of administering antiplatelet therapy before patients with STEMI reach the catheterization laboratory, and what would be needed to translate this approach into clinical practice.
Prof. Maria Bäck, Sahlgrenska University Hospital, Gothenburg, Sweden, and Chair of the ESC Guidelines Task Force, spoke with touchCARDIO about why the guidelines were needed, their key recommendations, and how clinicians can help improve participation in cardiac rehabilitation.
At ESC Congress 2026, Prof. Thomas Thum, Institute for Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany, discussed the future of molecular RNA-based therapies during the session Heart failure: hot off the press. He spoke with touchCARDIO about Phase II findings from the HF-REVERT study of microRNA-132 inhibition and what the results could mean for future development of RNA-based therapies.
Dr Jazmin Aguado-Sierra discusses how computational models and digital twins are helping researchers understand different heart failure phenotypes, and how artificial intelligence can accelerate analysis and support more personalized approaches.
Large language models, wearables and mobile health technologies are increasingly being explored across cardiovascular research and clinical care. At ESC Congress 2026, Dr Jazmin Aguado-Sierra discussed where these tools could add value, and where questions around reliability remain.
ESC Congress 2026 begins in Munich on August 28, bringing four days of new cardiovascular research, clinical guidance and discussion. Early data released ahead of the meeting provide a first look at some of the science to come.
